{"disease":{"id":"follicular-variant-thyroid-gland-papillary-carcinoma","name":"follicular variant thyroid gland papillary carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02973997","title":"Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT01811212","title":"Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03914300","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}